Skip to main content

Table 4 Univariate and multivariate Cox regression analyses for the risk of development of de novo donor-specific antibodies after kidney transplantation (p < 0.05)

From: Longitudinal monitoring of mRNA levels of regulatory T cell biomarkers by using non-invasive strategies to predict outcome in renal transplantation

VARIABLE

Univariate analysis

Multivariate analysisa

  

-2ln likelihood: 103.840

 

HR

95% CI

P

HR

95% CI

P

Baseline

      

Membrane CTLA4

0.479

0.181—1.263

0.137

—

—

—

Soluble CTLA4

0.296

0.126—0.694

0.005

0.189

0.078-0.459

<0.001

FOXP3

1.603

0.467—5.501

0.453

—

—

—

At 15 days

      

Membrane CTLA4

0.810

0.352—1.862

0.619

—

—

—

Soluble CTLA4

0.399

0.196—0.810

0.011

—

—

—

FOXP3

1.494

0.579—3.851

0.406

—

—

—

At 60 days

      

Membrane CTLA4

0.413

0.120—1.427

0.162

—

—

—

Soluble CTLA4

0.205

0.074—0.563

0.002

—

—

—

FOXP3

1.194

0.370—3.854

0.767

—

—

—

At 365 days

      

Membrane CTLA4

0.969

0.216—4.356

0.967

—

—

—

Soluble CTLA4

1.570

0.350—7.045

0.556

—

—

—

FOXP3

1.826

0.304—10.972

0.510

—

—

—

Recipient age

0.975

0.943—1.008

0.132

—

—

—

Donor age

1.003

0.977—1.029

0.847

—

—

—

Recipient gender

1.240

0.460—3.341

0.671

—

—

—

Donor gender

0.507

0.224—1.151

0.104

—

—

—

Type of dialysis

1.378

0.408—4.659

0.606

—

—

—

Dialysis duration

1.005

0.994—1.016

0.383

—

—

—

Don CMV IgG+/Rec CMV IgG-

1.201

0.355—4.060

0.768

—

—

—

Previous transplant

0.676

0.091—5.025

0.702

—

—

—

HLA mismatch

0.956

0.694—1.318

0.785

—

—

—

CIT (min)

0.999

0.998—1.001

0.411

—

—

—

WIT (min)

0.999

0.969—1.031

0.960

—

—

—

Type of donor

3.235

0.949—11.025

0.061

—

—

—

Type of induction

1.321

0.308—5.659

0.708

—

—

—

Chronic use of steroids

1.366

0.183—10.183

0.761

—

—

—

CNI (tacrolimus vs. cyclosporine)

0.743

0.218—2.529

0.635

—

—

—

PSI (mycophenolate vs. mTOR)

1.550

0.527—4.562

0.426

—

—

—

Immunosuppression change

1.330

0.524—3.376

0.549

—

—

—

Infratherapeutic CNI level at 15 days

1.020

0.430—2.424

0.964

—

—

—

Infratherapeutic CNI level at 60 days

1.002

0.442—2.275

0.996

—

—

—

DGF

0.958

0.406—2.263

0.922

—

—

—

CMV reactivation

0.605

0.206—1.780

0.361

—

—

—

  1. a Model summary: χ2(1)=14.217, p < 0.01. Covariates initially introduced in the multivariable model and then elided were: soluble CTLA4 at 15 days, soluble CTLA4 at 60 days
  2. Abbreviations: CI confidence intervals, CIT cold ischemia time, CMV cytomegalovirus, CNI calcineurin inhibitor, DGF delayed graft function, HLA human leukocytes antigens, HR hazard ratio, PRA panel-reactive antibodies, mTORi mammalian target of rapamycin inhibitor, PSI proliferation signal inhibitor, WIT warm ischemia time
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us